Sutro Biopharma, Inc.’s STRO share price has dipped by 5.51%, which has investors questioning if this is right time to buy.

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Vaxcyte (NASDAQ:PCVX – Get Free Report) had its target price lowered by investment analysts at Needham & Company LLC from ...

Vaxcyte (NASDAQ:PCVX – Free Report) had its price target cut by The Goldman Sachs Group from $138.00 to $100.00 in a report ...

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...

BofA lowered the firm’s price target on Vaxcyte (PCVX) to $137 from $157 following the company’s report of Phase 2 dose-finding data for VAX-24 ...

S&P 500 and Nasdaq hit their six-month low level on Monday as investors’ concerns rise over the upcoming Donald Trump’s ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

Starting your week in biotech, shares of San Carlos-based Vaxcyte tumbled on Monday by a whopping 54% after the company reported mixed results from a study of its pneumococcal vaccine in infants. The ...

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.

Shares of vaccine companies dropped after the Food and Drug Administration's top vaccine official was pushed out in a clash with Health and Human Services Secretary Robert F. Kennedy Jr.